DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Remus Pharmaceuticals Limited (REMUS) share price today?

Remus Pharmaceuticals Limited (REMUS) is trading at ₹1,016 on the NSE, up 0.44% on the day. Source: DocStoX.

What is the PE ratio of Remus Pharmaceuticals Limited?

Remus Pharmaceuticals Limited has a price-to-earnings (PE) ratio of 27.8 in the Healthcare sector.

What is the market capitalisation of Remus Pharmaceuticals Limited?

Remus Pharmaceuticals Limited has a market capitalisation of approximately ₹1,181 crore.

Is Remus Pharmaceuticals Limited a profitable company?

Remus Pharmaceuticals Limited generates a return on equity of 10.5% with a net profit margin of 5.4%. That is a modest return on shareholder capital.

What is the 52-week high and low of REMUS?

Remus Pharmaceuticals Limited (REMUS) has traded between ₹580 and ₹1,039 over the past 52 weeks, against a current price of ₹1,016.

Does Remus Pharmaceuticals Limited pay a dividend?

Yes. Remus Pharmaceuticals Limited currently offers a dividend yield of 0.06%. Dividend payments depend on the board's declaration each year.

Remus Pharmaceuticals Limited

₹1,016.00▲ +4.45 (+0.44%)

REMUS·NSE·Healthcare

Market Cap

1180.76 Cr

PE Ratio

27.80

Volume

3,700

Day High - Low

1016.00 - 1000.00

52W High-Low

1039.00 - 580.00

₹1,016.00▲ +4.45 (+0.44%)

Market Cap1180.76 Cr

PE Ratio27.80

Volume3,700

Day High - Low1016.00 - 1000.00

52W High-Low1039.00 - 580.00

Remus Pharmaceuticals Limited (REMUS): company summary

The company's annual revenue rose 37.7% year-over-year, while annual net profit increased 21.5%.

Remus Pharmaceuticals Limited (REMUS) is a micro-cap Healthcare company valued at ₹1,181 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Remus Pharmaceuticals Limited last traded at ₹1,016, modestly up 0.44% on the day.
Financial performance: The company's annual revenue rose 37.7% year-over-year, while annual net profit increased 21.5%. In the latest quarter, revenue grew 30.2% compared to the same quarter a year earlier, and net profit rose 19.0%.
Valuation multiples: The stock trades at 27.8 times earnings, broadly in line with the Healthcare median of 32.0, 3.00 times book value. It yields 0.1%.
Things to watch: The net profit margin narrowed 0.7 percentage points to 5.4%. The stock is 14.4% below its 52-week high. Promoter holding remains at 70.95%.
Where it stands: The company has shown strong revenue and profit growth over the past five years, with the latest quarter reflecting continued expansion. The stock is trading below its 52-week high, and the net profit margin has declined slightly.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

6.0/10

Fair

Fair Value

ROE

10.54%

Average

P/E

27.80x

Fair

Debt / Equity

0.08

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹1000

₹1016

52W₹580.00

₹1039

DocStoX take

Supported by growth (9.5) and risk (7.6), but held back by valuation (2.6). Growth looks strong at 9.5, but that is offset by valuation at 2.6. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

6.0

/10

Fair

Quality

Modest

ROE 10.5%

Valuation

Expensive

P/E 27.8×

Growth

Strong

Revenue +115.4% 5Y CAGR

Risk

Low risk

D/E 0.08

Momentum

Strong

95% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹1,016

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹1,181 Cr

52W High / Low

₹1039 / ₹580

Dividend Yield

0.06%

Promoter Holding

70.95%

EPS (TTM)

₹36.55

Book Value

₹297.95

Key highlights

Revenue compounding 115% a year
Profit compounding 114% a year
Low leverage — D/E 0.08

4 Positives0 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Remus Pharmaceuticals Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Remus Pharmaceuticals Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Remus Pharmaceuticals Limited with peers

Remus Pharmaceuticals Limited vs Sun Pharmaceutical Industries Limited Remus Pharmaceuticals Limited vs Divi's Laboratories Limited Remus Pharmaceuticals Limited vs Torrent Pharmaceuticals Limited Remus Pharmaceuticals Limited vs Apollo Hospitals Enterprise Limited Remus Pharmaceuticals Limited vs Zydus Lifesciences Limited Remus Pharmaceuticals Limited vs Laurus Labs Limited

Related tools & concepts

Value Remus Pharmaceuticals Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

REMUS newsLatest coverage & filings Open screenerFilter the whole market